Cargando…

Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer

Cyclin-dependent kinase (CDK)-7 inhibitors are emerging as promising drugs for the treatment of different types of cancer that show chemotherapy resistance. Evaluation of the effects of CDK7 inhibitor, THZ1, alone and combined with tamoxifen is of paramount importance. Thus, in the current work, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Attia, Yasmin M., Shouman, Samia A., Salama, Salama A., Ivan, Cristina, Elsayed, Abdelrahman M., Amero, Paola, Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215326/ https://www.ncbi.nlm.nih.gov/pubmed/32340192 http://dx.doi.org/10.3390/ijms21082974

Ejemplares similares

Back to the Future: Rethinking the Great Potential of lncRNA(S) for Optimizing Chemotherapeutic Response in Ovarian Cancer
por: Elsayed, Abdelrahman M., et al.
Publicado: (2020)

PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway
por: Elsayed, Abdelrahman M., et al.
Publicado: (2021)

An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer
por: Martinez-Castillo, Moises, et al.
Publicado: (2023)

Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology
por: Amero, Paola, et al.
Publicado: (2020)

Non-Coding RNAs: Foes or Friends for Targeting Tumor Microenvironment
por: Szymanowska, Anna, et al.
Publicado: (2023)

Explainable Artificial Intelligence Reveals Novel Insight into Tumor Microenvironment Conditions Linked with Better Prognosis in Patients with Breast Cancer
por: Chakraborty, Debaditya, et al.
Publicado: (2021)

Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update
por: Bayraktar, Emine, et al.
Publicado: (2023)

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges
por: Szymanowski, Wojciech, et al.
Publicado: (2023)

Targeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines
por: Attia, Yasmin M., et al.
Publicado: (2015)

Effect of Tumour Necrosis Factor-Alpha on Estrogen Metabolic Pathways in Breast Cancer Cells
por: Kamel, Marwa, et al.
Publicado: (2012)

Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer
por: Lara, Olivia D., et al.
Publicado: (2020)

Tankyrase inhibition sensitizes cells to CDK4 blockade
por: Foronda, Miguel, et al.
Publicado: (2019)

Inactivating Mutations of the IK Gene Weaken Ku80/Ku70-Mediated DNA Repair and Sensitize Endometrial Cancer to Chemotherapy
por: Gao, Chao, et al.
Publicado: (2021)

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

Molecular Design, Spectroscopic, DFT, Pharmacological, and Molecular Docking Studies of Novel Ruthenium(III)–Schiff Base Complex: An Inhibitor of Progression in HepG2 Cells
por: Noureldeen, Amani F. H., et al.
Publicado: (2022)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
por: Sarver, Melissa, et al.
Publicado: (2021)

Endocrine Mucin-Producing Sweat Gland Carcinoma, a Histological Challenge
por: Brett, Mary Anne, et al.
Publicado: (2017)

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

Rebound increase in microRNA levels at the end of 5-FU-based therapy in colorectal cancer patients
por: Badr, Doaa, et al.
Publicado: (2023)

Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression
por: Lin, Yueh-Te, et al.
Publicado: (2021)

Role of Napsin A and Survivin Immunohistochemical Expression in Bronchogenic Adenocarcinoma
por: Mohammed Salama, Maha Elsayed
Publicado: (2020)

Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer
por: Dasari, Santosh K., et al.
Publicado: (2023)

Socioeconomic Risk Factors for Preterm Birth in the state of Qatar: A Population-based Study
por: Salama, Elsayed Ibrahim Ali, et al.
Publicado: (2021)

Clinical Impact of Sugammadex in the Reversal of Neuromuscular Blockade
por: Goodner, Joshua A, et al.
Publicado: (2021)

CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis
por: Zhang, Shu, et al.
Publicado: (2015)

CDK1/2/5 blockade: killing two birds with one stone
por: Liu, Jiao, et al.
Publicado: (2021)

Association of TLR7 and TLR9 genes polymorphisms in Egyptian patients with systemic lupus erythematosus
por: Azab, Marwa M., et al.
Publicado: (2022)

Successful stories of drug repurposing for cancer therapy in hepatocellular carcinoma
por: Attia, Yasmeen M., et al.
Publicado: (2020)

Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition
por: He, Wei, et al.
Publicado: (2020)

DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway
por: Fan, Huimin, et al.
Publicado: (2023)

Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer
por: El-Kersh, Dina M., et al.
Publicado: (2021)

Simvastatin Evokes An Unpredicted Antagonism For Tamoxifen In MCF-7 Breast Cancer Cells
por: Ibrahim, Amel B, et al.
Publicado: (2019)

Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
por: Belli, Stefania, et al.
Publicado: (2023)

Modulation of Tamoxifen Cytotoxicity by Caffeic Acid Phenethyl Ester in MCF-7 Breast Cancer Cells
por: Motawi, Tarek K., et al.
Publicado: (2016)

PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
por: Ali, Lestat R., et al.
Publicado: (2023)

CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors
por: Salewski, Inken, et al.
Publicado: (2022)

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
por: Nabieva, Naiba, et al.
Publicado: (2023)

Observational study on patterns of neuromuscular blockade reversal
por: Dubovoy, Timur, et al.
Publicado: (2016)

Blockade of voltage-gated sodium channels inhibits invasion of endocrine-resistant breast cancer cells
por: MOHAMMED, FATIMA H., et al.
Publicado: (2015)

The CDK-activating kinase Cdk7: Taking yes for an answer
por: Schachter, Miriam Merzel, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1ovi2qarkqgbk8b4g77tl4ou7u